Biomarker Convert: a novel approach to transform plasma pTau217 results across immunoassay and mass spectrometry analytical platforms
Related Experiment Video
Updated: Oct 13, 2026
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Introduction:
We report the development and validation of a novel computational tool to cross-convert plasma pTau217 results from different assays to facilitate recruitment for therapeutic trials and observational studies.
Methods:
Participants underwent Aβ PET imaging and plasma pTau217 measurement on up to three assay platforms across three cohorts. We then developed conversion equations using Deming regression - collectively named Biomarker Convert - and evaluated robustness using independent research cohorts. Finally, we modeled the potential impact of pTau217 screening on trial enrollment.
Results:
While absolute plasma pTau217 concentrations differed, the assays had similar predictive characteristics for Aβ positivity (LC-MS/MS [C 2 N], AUC=0.952; Janssen Simoa, AUC=0.946; Lumipulse, AUC=0.929). Biomarker Convert enabled transformation of plasma pTau217 data across assays independent of Aβ PET and clinical status. Plasma pTau217 reduced Aβ PET scans in the model screening paradigm by >60%.
Discussion:
Biomarker Convert equations enable harmonization of plasma pTau217 values from immunoassay and mass spectrometry platforms, supporting direct data comparison.
